Skip to main content
SpringerLink
Log in

Appropriate Use of Interferon Beta-1a in Multiple Sclerosis

  • Disease Management
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Multiple sclerosis (MS), a chronic inflammatory demyelinating disease of the central nervous system, is the most common crippling neurological disease of young adults in the US. The 2 basic clinical forms of the disease (relapsing and progressive), which can occur singly or in combination, encompass a wide range of clinical severities are usually established between 18 and 35 years of age and can persist an entire lifetime. Life expectancy of 20 years is 85% of normal.

Historically, the standard proven and generally accepted clinical treatment of the disease has been corticotropin (ACTH) and methylprednisolone, which benefited clinical relapses but had no effect on clinical disability (the most important factor influencing the lives of individual MS patients) or other aspects of the chronic course of the disease. The most important new development in the treatment of MS has been the introduction of interferon beta into the clinic. Two forms of recombinant interferon beta have been approved by the FDA for use in relapsing MS: interferon beta-1b (IFN-β-1b) and interferon beta-1a (IFN-β-1a). The efficacy of IFN-β-1b in the treatment of relapsing-remitting MS was established first but no effect on physical disability progression was discerned.

In contrast, well designed trials of intramuscular IFN-β-1a (Avonex®) 6.0 MIU (30μ) weekly and subcutaneous IFN-α-1a (Rebif®) 6 MIU (22μg) or 12 MIU (44μg) 3 times weekly produced a significant delay in the time to sustained progression in physical disability, the first MS treatment to exert such a prophylactic effect. Additionally, IFN-β-1a significantly reduced clinical relapses and acute and chronic brain lesions revealed by MRI examinations. It is currently believed that IFN-β-1a treatment alters the fundamental course of relapsing MS.

The mechanisms of the therapeutic benefit of recombinant interferon betas are incompletely understood but may include augmentation of suppressor T cell function, inhibition of interferon gamma actions, inhibition of T cell activation, or induction of interleukin-10 gene transcription.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 1997; 120: 865–916

    Article  PubMed  Google Scholar 

  2. Dhib-Jalbut S, McFarlin DE. Immunology of multiple sclerosis. Ann Allergy 1990; 64: 433–44

    PubMed  CAS  Google Scholar 

  3. Julien J, Ferrer X. Multiple sclerosis: an overview. Biomed Pharmacother 1989; 43: 335–46

    Article  PubMed  CAS  Google Scholar 

  4. Traggs BD, Peterson J, Rarnsohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278–85

    Article  Google Scholar 

  5. Becker CC, Gidal BE, Fleming JO. Immunotherapy in multiple sclerosis. Pt 1. Am J Health Syst Pharm 1995; 52: 1985–2000

    CAS  Google Scholar 

  6. Hartung H-P. Immune-mediated demyelination. Ann Neurol 1993; 33: 563–7

    Article  PubMed  CAS  Google Scholar 

  7. Lucchinetti CF, Brück W, Rodriguez M, et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis [review]. Brain Pathol 1996; 6: 259–74

    Article  PubMed  CAS  Google Scholar 

  8. Sercarz EE, Lehmann PV, Ametani A, et al. Dominance and crypticity of T cell antigenic determinants [review]. Annu Rev Immunol 1993; 11: 729–66

    Article  PubMed  CAS  Google Scholar 

  9. Miller SD, McRae BL, Vanderlugt CL, et al. Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases [review]. Immunol Rev 1995 a; 144: 225–44

    Article  PubMed  CAS  Google Scholar 

  10. Genain CP, Nguyen M-H, Letvin NL, et al. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest 1995 a; 96: 2966–74

    Article  PubMed  CAS  Google Scholar 

  11. Wekerle H, Kojima K, Lannes-Vieira J, et al. Animal models [review]. Ann Neurol 1994; 36 Suppl.: S47–53

    Article  PubMed  CAS  Google Scholar 

  12. Cutler RWP. Demyelinating disease. In: Dale DC, Federman DD, Cassel CK, et al., editors. Scientific American medicine. New York, NY: Scientific American Inc., 1993; sect 11, chap IX: 1-8

    Google Scholar 

  13. Minden SL, Marder WD, Harrold LN, et al. Multiple sclerosis: a statistical portrait. Cambridge, (MA): ABT Associates, Inc., 1993

    Google Scholar 

  14. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol 1994; 36: S–6–11

    Article  Google Scholar 

  15. Mathews WB. Course and prognosis. In: Mathews WB, Compston A, Allen IV, et al., editors. McAlpine’s multiple sclerosis. 2nd ed. New York, NY: Churchill Livingstone, 1991: 139–63

    Google Scholar 

  16. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis. Neurology 1996; 46: 907–11

    Article  PubMed  CAS  Google Scholar 

  17. Kinkel RP, Rudick RA. Multiple sclerosis. In: Conn HF, editor. Current therapy. Philadelphia, (PA): WB Saunders Company, 1996: 883–93

    Google Scholar 

  18. Martyn CN. The epidemiology of multiple sclerosis. In: Mathews WB, Compston A, Allen IV, et al., editors. McAlpine’s multiple sclerosis. 2nd ed. New York, NY: Churchill Livingstone, 1991: 3–40

    Google Scholar 

  19. Compston A. Genetic epidemiology of multiple sclerosis. J Neurol Neurosurg Psychiat 1997; 62: 553–61

    Article  PubMed  CAS  Google Scholar 

  20. Kurtzke JF. Epidemiology of multiple sclerosis. In: Hallpike JF, Adams CW, Tourtellotte WW, editors. Multiple sclerosis. Baltimore, (MD): Williams & Wilkins, 1983: 47–96

    Google Scholar 

  21. Calder V, Owen S, Watson C, et al. MS: a localized immune disease of the central nervous system. In: Kelly J, Gallagher R, editors. Immunology today. New York, NY: Elsevier Science Publishers Ltd, 1989; 10: 99–103

    Google Scholar 

  22. Jacobs L, Goodkin DE, Rudick RA, et al. Advances in specific therapy for multiple sclerosis. Curr Opin Neurol 1994; 7: 250–4

    Article  PubMed  CAS  Google Scholar 

  23. Rose AS, Kuzma JW, Kurtzke JF, et al. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs placebo: final report. Neurology 1970; 20: 1–159

    PubMed  CAS  Google Scholar 

  24. Myers LW. Treatment of multiple sclerosis with ACTH and corticosteroids. In: Rudick RA, Goodkin DE, editors. Treatment of multiple sclerosis: trial design, results and future perspectives. London, England: Springer-Verlag, 1992: 135

    Google Scholar 

  25. Jacobs LD, Brownscheidle CM. Making strides in therapy for multiple sclerosis. Contemp Int Med 1997; 9: 33–40

    Google Scholar 

  26. Miller H, Newell DJ, Ridley A. Multiple sclerosis: treatment of acute exacerbations with corticotropin (ACTH). Lancet 1961; II: 1120–22

    Article  Google Scholar 

  27. Durelli L, Cocito D, Riccio A, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical immunologic correlations. Neurology 1986; 36: 238

    Article  PubMed  CAS  Google Scholar 

  28. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high-dose methylprednisolone in patients with multiple sclerosis. I. clinical effects. J Neurol Neurosurg Psychiat 1987; 50: 511

    Article  PubMed  CAS  Google Scholar 

  29. Hughes RAC. Use of azathioprine in multiple schlerosis. In: Cazzullo CL. Caputo D, Ghezzi A, et al., editors. Virology and immunology in multile schlerosis: rationale for therapy. Berlin: Springer-Verlag, 1988: 153–61

    Chapter  Google Scholar 

  30. Goodkin DE, Rudick RA, Vanderbrug Medendorp S, et al. Low-dose (7.5mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37: 30–41

    Article  PubMed  CAS  Google Scholar 

  31. Jacobs L, O’Malley J, Freeman A, et al. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 1981; 214: 1026–8

    Article  PubMed  CAS  Google Scholar 

  32. Jacobs L, Salazar AM, Herndon RM, et al. Multicenter doubleblind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet 1986; II: 1411–3

    Article  Google Scholar 

  33. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285–94

    Article  PubMed  CAS  Google Scholar 

  34. The IFN-β Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655–61

    Article  Google Scholar 

  35. Paty DB, Li DKB, the UBC MS/MRI Study Group, et al. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662–7

    Article  PubMed  CAS  Google Scholar 

  36. The IFN-β Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277–85

    Article  Google Scholar 

  37. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 1997; 49: 358–63

    Article  PubMed  CAS  Google Scholar 

  38. National Multiple Sclerosis Society. Research Programs Department News. Positive results announced for interferon beta-1a (Rebif®, Ares-Serono) for relapsing-remitting MS; 1997 Oct 3; News No. RP01-98

  39. Rudick RA, Simonian NA, Alam JD, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998; 50: 1266–72

    Article  PubMed  CAS  Google Scholar 

  40. The IFN-β Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889–94

    Article  Google Scholar 

  41. Hochuli E. Interferon immunogenecity: technical evaluation of interferon-alpha-2a. J Interferon Cytokine Res 1997; 17: S15–S21

    PubMed  CAS  Google Scholar 

  42. Wang C, Eufemi M, Turano C, et al. Influence of the carbohydrate moiety on the stability of glycoproteins. Biochemistry 1996; 35: 7299–307

    Article  PubMed  CAS  Google Scholar 

  43. Keck K. Ir gene control of carrier recognition. III. Cooperative recognition of two or more carrier determinants on insulins of different species. Eur J Immunol 1997; 7: 811–6

    Article  Google Scholar 

  44. Rosenwasser LJ, Barcinski MA, Schwartz RH, et al. Immune response gene control of determinant selection. II. Genetic control of the murine T lymphocyte proliferative response to insulin. J Immunol 1979; 123: 471–6

    PubMed  CAS  Google Scholar 

  45. Cohen IR, Talmon J. H-2 genetic control of the response of T lymphocytes to insulins. Priming of nonresponder mice by forbidden variants of specific antigenic determinants. Eur J Immunol 1980; 10: 284–9

    Article  PubMed  CAS  Google Scholar 

  46. Holliday SM, Benfield P. Interferon-β-1a: a review of its pharmacological properties and therapeutic potential in multiple sclerosis. BioDrugs 1997; 4: 317–30

    Article  Google Scholar 

  47. Avonex™ (Interferon beta-1a) IM injection. Product Monograph. 1996, Biogen, Inc.

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Buffalo General Hospital, and William C. Baird Multiple Sclerosis Research Center, Millard Fillmore Hospital, State University of New York at Buffalo, Buffalo, New York, USA

    Lawrence Jacobs & Carol M. Brownscheidle

  2. Department of Neurology, Buffalo General Hospital, 100 High Street, Buffalo, New York, 14203, USA

    Lawrence Jacobs

Authors
  1. Lawrence Jacobs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carol M. Brownscheidle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lawrence Jacobs.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jacobs, L., Brownscheidle, C.M. Appropriate Use of Interferon Beta-1a in Multiple Sclerosis. BioDrugs 11, 155–163 (1999). https://doi.org/10.2165/00063030-199911030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199911030-00002

Keywords

Search

Navigation